Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Recently diagnosed young adults with blood-related cancers have better long-term survival rates

A new analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s. Published in the November 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that significant advances have been made in the treatment of 15 to 24 year-olds with leukemias and lymphomas; however, survival rates in this age group are still lower than those seen in younger children.

24 Aug 2009

Scientific advancement in treating blood-related cancers leads to better survival rates

A recent analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s.

24 Aug 2009

Discovery of inherited gene variants that account for 37 percent of childhood acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.

16 Aug 2009

Tamoxifen kills fungus cells and may prevent them from causing disease

An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.

20 Jul 2009

Discovery 'significant step' in understanding leukaemia drug resistance

Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation.

8 Jun 2009

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009

Discovery of mutant genes in acute lymphoblastic leukemia

A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.

19 May 2009

Few physicians support private banking of umbilical cord blood

A survey of physicians has found broad support for the position that parents should not bank their newborns' umbilical cord blood in a private blood bank unless another member of the family is at risk for a blood disease that will require a stem cell transplant.

8 Mar 2009

New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease

The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofía Hospital in Cordoba, Andalusia.

8 Feb 2009

Research finds more than 100 gene variations linked with response to leukemia treatment

Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this cancer.

29 Jan 2009

Genetic variations associated with treatment response for acute lymphoblastic leukemia

Children with acute lymphoblastic leukemia with certain genetic variations can have a different response to anti-cancer treatment than other patients, according to a study in the January 28 issue of JAMA, the Journal of the American Medical Association.

29 Jan 2009

Gene abnormality found to predict childhood leukemia relapse

Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).

8 Jan 2009

Gene mutations found to predict acute lymphoblastic leukemia relapse

Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).

7 Jan 2009

Men who survive childhood leukemia have lower bone mineral density

Men who survived childhood leukemia treatment into adulthood were more likely to have low bone mineral density than other adults their age, putting them at risk of osteoporosis and bone fractures, according to a new study.

3 Dec 2008

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse.

28 Nov 2008

Potential new therapeutic targets for rejuvenating the aged immune system

In the November 15th issue of G&D, Dr. Kenneth Dorshkind and colleagues at the David Geffen School of Medicine (UCLA) have identified two genes - p16(Ink4a) and Arf - that sensitize lymphoid progenitor cells to the effects of aging, and confer resistance to leukemogenesis.

16 Nov 2008